A research team from the Eye & ENT Hospital of Fudan University, China, has developed a novel biocompatible nanoadhesive for ...

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company ...

ARLINGTON, Mass. - KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on developing treatments for rare and severe eye diseases, announced a change in its executive leadership on Monday ...

Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ ... patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

Prothena (NASDAQ:PRTA – Get Free Report) and KALA BIO (NASDAQ:KALA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses ...

After hours: February 14 at 5:17:30 PM EST Loading Chart for TECH ...

This concerns how much of an astigmatism you have. Astigmatism occurs when the cornea or lens of the eye is more curved than it should be, which results in the eye being unable to focus light ...

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.